Oncotarget

Research Papers:

Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database

Matthew MacLean, Xin Luo, Shidan Wang, Kemp Kernstine, David E. Gerber _ and Yang Xie

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:24470-24479. https://doi.org/10.18632/oncotarget.25327

Metrics: PDF 407 views  |   HTML 738 views  |   ?  


Abstract

Matthew MacLean1, Xin Luo2, Shidan Wang1, Kemp Kernstine3, David E. Gerber4,5 and Yang Xie1,2,5

1Quantitative Biomedical Research Center, Department of Clinical Sciences, University of Texas, Southwestern Medical Center, Dallas, Texas, USA

2Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, Texas, USA

3Department of Cardio Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA

4Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

5Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Correspondence to:

David E. Gerber, email: david.gerber@utsouthwestern.edu

Yang Xie, email: yang.xie@utsouthwestern.edu

Keywords: lung cancer; neoadjuvant chemotherapy; national cancer database

Received: September 30, 2017     Accepted: March 27, 2018     Published: May 11, 2018

ABSTRACT

Introduction: The current recommendation for the treatment of stage II and III NSCLC is surgery with chemotherapy. While the convention is to administer chemotherapy postoperatively (adjuvant chemotherapy), inconsistent results have been reported regarding the administration of chemotherapy preoperatively (neoadjuvant chemotherapy). Therefore, a comprehensive analysis of neoadjuvant chemotherapy use in NSCLC is needed.

Results: Of the 35,134 NSCLC patients identified, 18,684 received surgery alone, 1,154 received surgery with neoadjuvant chemotherapy, and 15,296 received surgery with adjuvant chemotherapy. Race, Charlson-Deyo score, facility type, insurance type and stage of disease are associated with the use of neoadjuvant chemotherapy. In the case of stage II disease, adjuvant chemotherapy showed improved survival (median OS = 80.8 months) over neoadjuvant chemotherapy (OS = 67.0 months) and surgery alone (OS = 51.0 months). For stage III disease, adjuvant chemotherapy (OS = 49.0 months) showed improved survival over surgery alone (OS = 24.3 months), followed by neoadjuvant chemotherapy (OS = 42.0 months). After propensity score matching, adjuvant chemotherapy was found to provide a survival advantage over neoadjuvant in both stage II (HR = 0.70; p = 5.8e-3) and stage III (HR = 0.77; p = 0.011) NSCLC.

Conclusions: Our analysis finds a survival advantage for neoadjuvant chemotherapy when compared to surgery alone, but no advantage compared to adjuvant chemotherapy in the treatment of resectable stage II and III NSCLC.

Methods: The National Cancer Database (NCDB) was queried for all cases of stage II and III NSCLC from 2006 to 2012. These patients were stratified by stage, and the factors affecting use of neoadjuvant chemotherapy and the effects of neoadjuvant versus adjuvant chemotherapy on overall survival (OS) were investigated.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25327